Via Egidio Folli 50   
I-20134 Milan - Italy

Phone: (+39) 02 2177.1


Bracco today :

Bracco is an international Group active in the healthcare sector including BraccoImaging (Diagnostic Imaging), Pharma (prescription and over the counter drugs) and the Centro Diagnostico Italiano diagnostic clinic in Milan. It has more than 3300 employees and annual total consolidated revenues of over 1,1 billion euros, of which 75% from international sales. In the Research and Innovation area, the company invests approximately 9% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 1,800 patents.

Bracco Imaging

The Bracco subsidiary, Bracco Imaging, is one of the world’s leading companies in the Diagnostic Imaging. It offers a products, injectors and solutions portfolio for all diagnostic applications: X-Ray Imaging (including Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound, and Nuclear Medicine. Imaging agents are pharmaceutical products aimed at supporting diagnosis and monitoring of various pathologies.

Bracco Pharma

In Italy, Bracco Group is a key player in many strategically important therapeutic fields, including gastroenterology, neurology, endocrinology and cardio-vascular pathology, where it markets own-brand drugs or pharmaceuticals under license. Bracco SpA is present in the territory through a network of 240 pharmaceutical representatives, supported by a diffused sales organization. This network has acquired a high reputation amongst pharmacists.

Bracco Centro Diagnostico Italiano

Another important area of activity of the Bracco Group regards the healthcare services provided by the Centro Diagnostico Italiano, a polyclinic based in Milan. With 21 satellite units in the city and in Lombardy, CDI offers different services of prevention, diagnosis, rehabilitation and personalized treatment, with a focus on radio-surgery and on day-surgery.

The Bracco Foundation

Since its creation Bracco is a socially responsible company in each area of activity. The Bracco foundation is part of the  family and company vision. Major initiatives of the CSR are promoting welfare and solidarity schemes, supporting employees with health prevention, building relationships with the land to create social innovation and sustainability, working closely with associations, local authorities and NGOs, circulating expression of culture, science and art.

1927 - Elio Bracco establishes a pharmaceutical business in Milan



1934 - Fulvio Bracco, Elio’son, joins the company



1946 - Bracco presents a new contrast agent


1948 - Key event on the market with the debut of a product of great importance: DIAZIL



1953 - Opening of new factory (LAMBRATE)



1966 - Diana Bracco joins the company



1981 - Launch of IOPADIMOL non ionic contrast agent



2001 - Opening of Bracco Research Center



2002 - Opening of SPIN, a unit dedicated to X-Ray



2007 - Acquisition of EZ-EM, leader in contrast agents